Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.
You may also be interested in...
Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave
The Contrave "complete response" letter could mean research in the category is sidelined now that all three of the current obesity drug candidates have been rejected.
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
Mural Oncology Primed For IL-2 Readouts Next Year
The company, which Alkermes spun out last year, is now positioned as a pure-play oncology specialist with a focus on cytokines.